We are proud to announce that we have treated more than 100 patients with the anti-amyloid Alzheimer’s disease medication, lecanemab (marketed as Leqembi), under the leadership and expertise of Dr. David Weisman. This milestone marks a significant step in the ongoing fight against Alzheimer’s, providing hope for patients and families.

Lecanemab is one of the first FDA-approved treatments to address the underlying cause of Alzheimer’s disease by targeting and reducing amyloid plaques in the brain. As an FDA approved treatment, it slows the progression of cognitive decline and functional impairment in patients with early-stage Alzheimer’s.

“Our mission at Abington Neurological Associates has always been patient wellbeing. That includes helping to develop the medications that are now standard of care. We are thrilled to have dosed over 100 patients with lecanemab, helping them slow the disease. This treatment, and these 100 people, represent a new era in Alzheimer’s treatments,” said Dr. David Weisman, a neurologist and clinical trialist in Alzheimer’s disease at ANA. “We are committed to serving our patients. We are proud to offer access to this medication, and develop other medications to arrest any progression and provide better symptomatic control.”

ANA remains dedicated to continuing our legacy as a clinical trial site and offering potentially therapeutic options for patients with Alzheimer’s and other neurologic diseases. Since 2008, the ANA trial center has conducted many dozens of clinical trials in AD, MCI, and prevention. This work continues.

For information about lecanemab treatment and patient eligibility, call us at 215-957-9250.